Details for New Drug Application (NDA): 020259
✉ Email this page to a colleague
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
Summary for 020259
Tradename: | MEPRON |
Applicant: | Glaxosmithkline Llc |
Ingredient: | atovaquone |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020259
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Nov 25, 1992 | TE: | RLD: | Yes |
Expired US Patents for NDA 020259
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | MEPRON | atovaquone | TABLET;ORAL | 020259-001 | Nov 25, 1992 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription